BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open 2013;3:e003231. [PMID: 24002983 DOI: 10.1136/bmjopen-2013-003231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 ANRS CO13 HEPAVIH Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. AIDS 2015;29:1821-30. [PMID: 26372388 DOI: 10.1097/QAD.0000000000000787] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
2 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
3 Tran AN, Sachdev R, Fricker ZP, Leber M, Zahorian T, Shah B, Nunes DP, Long MT. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital. Dig Dis Sci 2018;63:3241-9. [PMID: 30078116 DOI: 10.1007/s10620-018-5231-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med 2017;15:204. [PMID: 29151365 DOI: 10.1186/s12916-017-0969-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
5 Chang L, Chang H, Chen P, Chen C, Tsai K, Yean K, Yang H, Chen T, Yu P, Chou C, Chen S. Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan. Medicina 2022;58:521. [DOI: 10.3390/medicina58040521] [Reference Citation Analysis]
6 Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61:730-740. [PMID: 25987643 DOI: 10.1093/cid/civ396] [Cited by in Crossref: 184] [Cited by in F6Publishing: 167] [Article Influence: 26.3] [Reference Citation Analysis]
7 Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;Epub ahead of print. [PMID: 32119034 DOI: 10.1001/jama.2019.20788] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
8 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]